Patents by Inventor Rengyun Liu

Rengyun Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • REGULATION OF MUTANT TERT BY BRAF V600E/MAP KINASE PATHWAY THROUGH FOS/GABP IN HUMAN CANCER
    Publication number: 20240366544
    Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for the treatment of cancer characterized by TERT and BRAF mutations. In a specific embodiment, a method for treating a mutant telomerase reverse trancriptase (TERT) enzyme-associated cancer in a subject comprises the step of administering to the subject an anti-cancer agent that inhibits one or more of FOS, GABPB, the formation of the GABPA-GABPB complex or the binding of the GABPA-GABPB complex to a mutant TERT promoter.
    Type: Application
    Filed: January 26, 2024
    Publication date: November 7, 2024
    Inventors: Michael Mingzhao Xing, Rengyun Liu
  • Regulation of mutant TERT by BRAF V600E/map kinase pathway through FOS/GABP in human cancer
    Patent number: 11911356
    Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for the treatment of cancer characterized by TERT and BRAF mutations. In a specific embodiment, a method for treating a mutant telomerase reverse trancriptase (TERT) enzyme-associated cancer in a subject comprises the step of administering to the subject an anti-cancer agent that inhibits one or more of FOS, GABPB, the formation of the GABPA-GABPB complex or the binding of the GABPA-GABPB complex to a mutant TERT promoter.
    Type: Grant
    Filed: December 22, 2018
    Date of Patent: February 27, 2024
    Assignee: The Johns Hopkins University
    Inventors: Michael Mingzhao Xing, Rengyun Liu
  • REGULATION OF MUTANT TERT BY BRAF V600E/MAP KINASE PATHWAY THROUGH FOS/GABP IN HUMAN CANCER
    Publication number: 20200323805
    Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for the treatment of cancer characterized by TERT and BRAF mutations. In a specific embodiment, a method for treating a mutant telomerase reverse trancriptase (TERT) enzyme-associated cancer in a subject comprises the step of administering to the subject an anti-cancer agent that inhibits one or more of FOS, GABPB, the formation of the GABPA-GABPB complex or the binding of the GABPA-GABPB complex to a mutant TERT promoter.
    Type: Application
    Filed: December 22, 2018
    Publication date: October 15, 2020
    Inventors: Michael Mingzhao Xing, Rengyun Liu